Parameter | Assumed input value at GOLD stages | Assumed probability distribution at GOLD stages | ||
---|---|---|---|---|
II | III | II | III | |
Annual COPD mortality [20] | 0.00393 | 0.006762 | -- | -- |
Utility and disutilities [19] | Â | Â | ||
Baseline | 0.72 | 0.67 | B(160, 62) | B(59, 29) |
Minor exacerbation | 0.658 | 0.475 | B(164, 85) | B(47, 52) |
Major exacerbation | 0.447 | 0.408 | B(22, 27) | B(39, 57) |
Exacerbations rates and probabilities [19] | Â | Â | Â | |
Frequency | 1.22 | 1.47 | Γ(14884, 12200) | Γ(21609, 14700) |
Minor (%) | 0.93 | 0.90 | Γ(8649, 9300) | Γ(8100, 9000) |
Major (%) | 0.07 | 0.10 | Γ(12.25, 175) | Γ(25, 250) |
Minor exacerbation | 80$ | 134$ | Γ(320, 4) | Γ(536, 4) |
Major exacerbation | 3250$ | 5417$ | Γ(13000, 4) | Γ(21668, 4) |
Indirect maintenance cost [20] | 215$ | 524$ | Γ(860, 4) | Γ(2096, 4) |
Direct exacerbations costs ($) [19] | Â | Â | Â | Â |
Minor exacerbations | 161$ | Γ(644, 4) | ||
Major exacerbations | 6501$ | Γ(26004, 4) | ||
General practitioner visit | 70$ | Γ(280, 4) | ||
Specialist visit | 90$ | Γ(360, 4) | ||
Direct medication costs ($) [ [22] | Â | Â | Â | |
Inhaled corticosteroids (ICS) | 450$ | -- | ||
Long-acting beta-agonists (LABA) | 500$ | -- | ||
ICS + LABA | 1000$ | -- | ||
Long-acting muscarinic agents | 750$ | -- |